Diagonal launches with $128M and a platform slanted toward agonist antibodies mbayer Tue, 04/02/2024 - 16:35
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24 aarmstrong Tue, 04/02/2024 - 14:55
Roivant’s inflammatory med gets back on track with phase 2 eye disease data mbayer Tue, 04/02/2024 - 10:41
J&J targets rare maternal-fetal diseases: 'We're going for this. No one else has.' gmasson Tue, 04/02/2024 - 10:25
Gilead dives deeper into Nurix protein degrader collab, paying $15M for 2-year extension jwaldron Tue, 04/02/2024 - 08:51
Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck, Boehringer jwaldron Tue, 04/02/2024 - 06:21
Gritstone ground down by phase 2 cancer vaccine fail, sparking race against cash to gather more data ntaylor Tue, 04/02/2024 - 05:10
Headlands opens final clinical trial site in Pfizer diversity partnership hfloersh Mon, 04/01/2024 - 18:17
Verve halts enrollment of lead trial after grade 3 side effects, prioritizing next-up PCSK9 editor mbayer Mon, 04/01/2024 - 17:47
In major step toward the clinic, Ring’s human viral vector delivers gene therapy to eyes of mice hfloersh Mon, 04/01/2024 - 17:41
